Application of urine proteomics in the diagnosis and treatment effectiveness monitoring of early-stage Mycosis Fungoides

• Published in: Clinical proteomics Vol. 21; no. 1; p. 53
• Main Authors: Song, Hongbin, Hu, Zhonghui, Zhang, Shiyu, Yang, Lu, Feng, Jindi, Lu, Lu, Liu, Yuehua, Wang, Tao
• Format: Journal Article
• Language: English
• Published: London BioMed Central 13.08.2024; BioMed Central Ltd
• Subjects: 1-Phosphatidylinositol 3-kinase; AKT protein; Atopic dermatitis; Biological response modifiers; Biomarkers; Biomedical and Life Sciences; Biopsy; Biotechnology; Calcium signalling; Care and treatment; Cell Biology; Chromatography; Dermatitis; Diabetes; Diagnosis; Disease; Endocytosis; Enzyme-linked immunosorbent assay; Enzymes; Epidermal growth factor; Erythema; Fungal infections; Genomics; Hospitals; Interferon alpha; Life Sciences; Light therapy; Liquid chromatography; Lymphocytes T; Lymphoma; MAP kinase; Mass spectrometry; Mass spectroscopy; Medical prognosis; Medical research; Medical schools; Mycoses; Mycosis; Mycosis fungoides; Non-Hodgkin's lymphomas; Pathology; Patients; Phospholipase D; Phototherapy; Pityriasis; Proteins; Proteomes; Proteomics; Psoriasis; Scientific imaging; Skin; Skin diseases; T cells; Tumors; Urine; China; Beijing China; Urine; Mycosis fungoides; Cutaneous T cell lymphoma; Mass spectrometry; Proteomics
• ISSN: 1542-6416; 1559-0275
• DOI: 10.1186/s12014-024-09503-7

Background Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma. As the early clinical manifestations of MF are non-specific (e.g., erythema or plaques), it is often misdiagnosed as inflammatory skin conditions (e.g., atopic dermatitis, psoriasis, and pityriasis rosea), resulting in delayed treatment. As there are no effective biological markers for the early detection and management of MF, the aim of the present study was to perform a proteomic analysis of urine samples (as a non-invasive protein source) to identify reliable MF biomarkers. Methods Thirteen patients with early-stage MF were administered a subcutaneous injection of interferon α-2a in combination with phototherapy for 6 months. The urine proteome of patients with early-stage MF before and after treatment was compared against that of healthy controls by liquid chromatography-tandem mass spectrometry. The differentially expressed proteins were subjected to Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Clusters of Orthologous Groups analyses. For validation, the levels of the selected proteins were evaluated by enzyme-linked immunosorbent assay (ELISA). Results We identified 41 differentially expressed proteins (11 overexpressed and 30 underexpressed) between untreated MF patients and healthy control subjects. The proteins were mainly enriched in focal adhesion, endocytosis, and the PI3K-Akt, phospholipase D, MAPK, and calcium signaling pathways. The ELISA results confirmed that the urine levels of Serpin B5, epidermal growth factor (EGF), and Ras homologous gene family member A (RhoA) of untreated MF patients were significantly lower than those of healthy controls. After 6 months of treatment, however, there was no significant difference in the urine levels of Serpin B5, EGF, and RhoA between MF patients and healthy control subjects. The area under the receiver operating characteristic curve values for Serpin B5, EGF, and RhoA were 0.817, 0.900, and 0.933, respectively. Conclusions This study showed that urine proteomics represents a valuable tool for the study of MF, as well as identified potential new biomarkers (Serpin B5, EGF, and RhoA), which could be used in its diagnosis and management.